Ascletis Pharma Inc.

SEHK:1672 Stock Report

Market Cap: HK$1.6b

Ascletis Pharma Future Growth

Future criteria checks 0/6

Ascletis Pharma's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 117.7% per year. EPS is expected to decline by 3.5% per annum.

Key information

-4.1%

Earnings growth rate

-3.5%

EPS growth rate

Biotechs earnings growth42.2%
Revenue growth rate117.7%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Oct 2024

Recent future growth updates

Recent updates

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Oct 07
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03
What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13
Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27
Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

SEHK:1672 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202677-289N/AN/A1
12/31/2025N/A-298N/AN/A1
12/31/2024N/A-281N/AN/A1
6/30/202410-258-299-280N/A
3/31/202433-202-231-212N/A
12/31/202357-145-163-144N/A
9/30/202359-194-169-157N/A
6/30/202362-243-173-171N/A
3/31/202358-279-195-187N/A
12/31/202254-315-217-202N/A
9/30/202266-246-198-182N/A
6/30/202279-176-179-161N/A
3/31/202278-188-167-154N/A
12/31/202177-199-154-147N/A
9/30/202158-234-172-150N/A
6/30/202140-269-190-153N/A
3/31/202137-239-157-119N/A
12/31/202035-209-124-85N/A
9/30/202082-155-86-56N/A
6/30/2020130-100-47-28N/A
3/31/2020152-98-75-51N/A
12/31/2019173-96-103-74N/A
9/30/2019150-92-130-91N/A
6/30/2019127-89-157-107N/A
3/31/2019153-43-146-83N/A
12/31/2018166-7-157-97N/A
9/30/2018154-5-172-134N/A
6/30/2018142-2-188-171N/A
3/31/201891-40N/A-210N/A
12/31/201753-54N/A-198N/A
12/31/201633-27N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1672 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1672 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1672 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1672 is forecast to have no revenue next year.

High Growth Revenue: 1672 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1672's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y